WO2001087270B1 - Vaccine composition, method of preparing the same, and method of vaccinating vertebrates - Google Patents

Vaccine composition, method of preparing the same, and method of vaccinating vertebrates

Info

Publication number
WO2001087270B1
WO2001087270B1 PCT/US2001/015235 US0115235W WO0187270B1 WO 2001087270 B1 WO2001087270 B1 WO 2001087270B1 US 0115235 W US0115235 W US 0115235W WO 0187270 B1 WO0187270 B1 WO 0187270B1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine composition
vertebrate species
antigen
administering
microparticles
Prior art date
Application number
PCT/US2001/015235
Other languages
French (fr)
Other versions
WO2001087270A2 (en
WO2001087270A3 (en
Inventor
Terry L Bowersock
Paul Guimond
Tzu-Chi R Ju
Argaw Kidane
Original Assignee
Upjohn Co
Terry L Bowersock
Paul Guimond
Tzu-Chi R Ju
Argaw Kidane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Terry L Bowersock, Paul Guimond, Tzu-Chi R Ju, Argaw Kidane filed Critical Upjohn Co
Priority to DE60112073T priority Critical patent/DE60112073T2/en
Priority to AU2001261433A priority patent/AU2001261433A1/en
Priority to DK01935330T priority patent/DK1280521T3/en
Priority to AT01935330T priority patent/ATE299696T1/en
Priority to EP01935330A priority patent/EP1280521B1/en
Publication of WO2001087270A2 publication Critical patent/WO2001087270A2/en
Publication of WO2001087270A3 publication Critical patent/WO2001087270A3/en
Publication of WO2001087270B1 publication Critical patent/WO2001087270B1/en
Priority to HK03101999A priority patent/HK1049800A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a cellulose ether and at least one nonionic surfactant or (b) a PEO-PPO-PEO triblock copolymer surfactant and at least one nonionic surfactant; followed by crosslinking the alginate in the emulsion with at least two cations selected from the group consisting of aluminum, barium, calcium, lithium, manganese, strontium, and zinc, to form antigen-containing, crosslinked alginate microparticles; and harvesting the microparticles. Another aspect of the invention is a method of vaccinating a vertebrate species including the step of administering to the species a vaccine composition prepared according to the method of the invention. The compositions of the invention have improved antigen loading, reduced microparticle size, increased hydrophobicity, improved uptake by antigen sampling cells, controlled antigen release characteristics, and improved immunogenicity.

Claims

AMENDED CLAIMS
[received by the International Bureau on 17 May 2002 (17.05.02); new claims 43-45 added; remaining claims unchanged (1 page)]
(B) crosslinking the alginate in the emulsion of step (A) with zinc acetate and calcium acetate, to foi antigen-containing crosslinked alginate microparticles; and
(C) harvesting the microparticles of step (B).
36. A vaccine composition made by the method of any one of claims 1-34.
37. A vaccine composition made by the method of claim 35.
38. A method of vaccinating a vertebrate species comprising the step of administering to said vertebrate species a vaccine composition made by the method of any one of claims 1-34.
39. The method of claim 38 wherein said step of administering said vaccine composition is performed orally.
40. A method of vaccinating a vertebrate species comprising the step of administering to said vertebrate species a vaccine composition made by the method of claim 35.
41. A method of provoking an immune response in a vertebrate species comprising the step of administering to said vertebrate species a vaccine composition made by the method of any one of claims 1-34.
42. A method of provoking an immune response in a vertebrate species comprising the step of administering to said vertebrate species a vaccine composition made by the method of claim 35.
43. The method of any one of claims 1-35, wherein said antigen is selected from live viruses, live bacteria, labile proteins, nucleic acids, and combinations thereof.
44. A vaccine composition according to any one of claims 37 and 38, wherein the mean volume particle size of the microparticles before sonication is 6 μm or less.
45. A vaccine composition according to any one of claims 37 and 38, wherein the hydrophilicity index of the microparticles is 0.6 or less.
46 Transmitted herewith is substitute page 45, which has hem anaiended piur-aiamt to Article 19 of the Patent Cooperation Treaty. According to 1i-e amendments, new claims 43-45 have been added.
No new matter has been introduced by the foregting claim aKtemdments. Support for the amended claims is found in the claims a&j& specification as originally filed, for example, at page 14, lines 15-19; in Example 1, page 23, lines 15-18 and Figure 1; and in Example 1, page 24, lines 10-16, and Figure 4. ϊn accordance with Rule 62.2, copies of the amendment an accompanying statement are being filed with the European Patent Office (IPEA EP).
Entry of the foregoing amendments is solicited.
47
PCT/US2001/015235 2000-05-12 2001-05-11 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates WO2001087270A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60112073T DE60112073T2 (en) 2000-05-12 2001-05-11 VACCINATE COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE VACCINATION OF SWIVELED ANIMALS
AU2001261433A AU2001261433A1 (en) 2000-05-12 2001-05-11 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
DK01935330T DK1280521T3 (en) 2000-05-12 2001-05-11 Vaccine composition, method of preparation thereof and method of vaccination of vertebrates
AT01935330T ATE299696T1 (en) 2000-05-12 2001-05-11 VACCINE COMPOSITION AND METHOD FOR PRODUCING THE SAME AND METHOD FOR VACCINATION OF VERTEBRATE ANIMALS
EP01935330A EP1280521B1 (en) 2000-05-12 2001-05-11 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
HK03101999A HK1049800A1 (en) 2000-05-12 2003-03-18 Vaccine composition, method of preparing the same,and method of vaccinating vertebrates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20386400P 2000-05-12 2000-05-12
US60/203,864 2000-05-12

Publications (3)

Publication Number Publication Date
WO2001087270A2 WO2001087270A2 (en) 2001-11-22
WO2001087270A3 WO2001087270A3 (en) 2002-05-16
WO2001087270B1 true WO2001087270B1 (en) 2002-08-15

Family

ID=22755628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015235 WO2001087270A2 (en) 2000-05-12 2001-05-11 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates

Country Status (10)

Country Link
US (2) US6656470B2 (en)
EP (1) EP1280521B1 (en)
AT (1) ATE299696T1 (en)
AU (1) AU2001261433A1 (en)
DE (1) DE60112073T2 (en)
DK (1) DK1280521T3 (en)
ES (1) ES2243497T3 (en)
HK (1) HK1049800A1 (en)
PT (1) PT1280521E (en)
WO (1) WO2001087270A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ATE299696T1 (en) * 2000-05-12 2005-08-15 Pharmacia & Upjohn Co Llc VACCINE COMPOSITION AND METHOD FOR PRODUCING THE SAME AND METHOD FOR VACCINATION OF VERTEBRATE ANIMALS
WO2002069985A2 (en) * 2001-03-05 2002-09-12 Forinnova As Immune response potentiation
FR2823119B1 (en) * 2001-04-05 2004-02-20 Seppic Sa IMMUNITY ADJUVANT CONTAINING COMPLEX METAL CATION AND VACCINE CONTAINING SAME
US6962813B2 (en) * 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US7119172B2 (en) * 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US6678583B2 (en) * 2001-08-06 2004-01-13 Seminet, Inc. Robotic storage buffer system for substrate carrier pods
US7039499B1 (en) * 2002-08-02 2006-05-02 Seminet Inc. Robotic storage buffer system for substrate carrier pods
KR100548925B1 (en) * 2002-10-23 2006-02-02 한미약품 주식회사 Sustained release composition for oral administration of a drug
ES2496102T3 (en) * 2003-03-28 2014-09-18 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
US20040235770A1 (en) * 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US7081227B2 (en) * 2004-06-07 2006-07-25 The Reagents Of The University Of California Amphiphilic mediated sample preparation for micro-flow cytometry
US20060062779A1 (en) * 2004-09-21 2006-03-23 The Brigham And Women's Hospital, Inc. Methods and compositions relating to mannuronic acid specific binding peptides
WO2006035418A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
WO2006059846A1 (en) * 2004-12-01 2006-06-08 Lg Life Sciences, Ltd. Formulation of sec1 mutated protein and method for formulation of the same
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
WO2007084500A2 (en) * 2006-01-13 2007-07-26 Advanced Bionutrition Corporation Continuous spray-capture production system
EP2066309B1 (en) 2007-04-04 2012-08-29 Sigmoid Pharma Limited An oral pharmaceutical composition
EP2586428B1 (en) * 2007-04-26 2023-11-08 Sublimity Therapeutics Limited Manufacture of multiple minicapsules
JP2010526053A (en) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド Nimodipine pharmaceutical composition
US8709827B2 (en) * 2007-06-28 2014-04-29 Surmodics, Inc. Polypeptide microparticles
SI2432455T1 (en) 2009-05-18 2015-04-30 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) * 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20140356396A1 (en) * 2011-08-25 2014-12-04 Brian L. Pulliam Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
KR20160095124A (en) 2013-12-06 2016-08-10 어드밴스드 바이오뉴트리션 코포레이션 Composition for oral delivery of bioactive agents
CA2966801A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
WO2017097844A1 (en) * 2015-12-07 2017-06-15 Schlumberger Norge As Microsphere compositions and methods for production in oil-based drilling fluids
GB202205231D0 (en) * 2022-04-09 2022-05-25 Nasaleze Patents Ltd Vaccine compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1050353B (en) 1966-01-06 1981-03-10 Ceskoslovenska Akademie Ved SUPPORTS FOR BIOLOGICALLY ACTIVE SUBSTANCES
EG10802A (en) 1971-02-19 1976-10-31 Bayer Ag A process for embeding veterinary substances and their protection against the influence of the gastric juice of the rumen
US4178361A (en) 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
US4220152A (en) 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4798786A (en) 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
CA1196862A (en) 1983-06-01 1985-11-19 Anthony M.F. Sun Microencapsulation of living tissue and cells
US4806355A (en) 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
GB8326633D0 (en) 1983-08-04 1983-11-09 Unilever Plc Compositions
US4803168A (en) 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
GB8500121D0 (en) 1985-01-03 1985-02-13 Connaught Lab Microencapsulation of living cells
JPS62502262A (en) 1985-03-27 1987-09-03 ブロンコスタット・プロプライアタリー・リミテツド Vaccines without adjuvants
US4780315A (en) 1985-11-25 1988-10-25 Eastman Kodak Company Rumen-stable pellets
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
NL8701548A (en) * 1987-07-01 1989-02-01 Tno POLYMER NETWORK, METHOD FOR THE PREPARATION THEREOF, THE USE THEREOF FOR CLADING AND / OR IMPREGNATING OR FOR MANUFACTURING EYE LENSES, AND FORMED PROPERTIES, WHOLLY OR FROM AN EXISTINGLY PROVEN POLISH.
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4808404A (en) 1988-01-11 1989-02-28 A. H. Robins Company, Inc. Live vaccine for coccidiosis utilizing coccidial sporozoites
JPH01313437A (en) 1988-06-14 1989-12-18 Nippon Seibutsu Kagaku Kenkyusho Particulate live vaccine for administration into feed, production thereof and live vaccine for avian coccidiosis
FR2683147B1 (en) 1991-10-30 1995-06-23 Maingault Philippe VEHICLE SYSTEM OF ACTIVE INGREDIENT FOR ORAL ADMINISTRATION IN FISH AND CRUSTACEANS.
US5352448A (en) 1992-07-20 1994-10-04 Purdue Research Foundatioin Oral administration of antigens
CA2167081A1 (en) 1993-07-12 1995-01-26 Alexander K. Andrianov Hydrogel microencapsulated vaccines
US5674495A (en) 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
KR20010003853A (en) * 1999-06-25 2001-01-15 박호군 Vaccine compositions using antigens encapsulated within alginate microspheres for oral administration and preparation process thereof
ATE299696T1 (en) * 2000-05-12 2005-08-15 Pharmacia & Upjohn Co Llc VACCINE COMPOSITION AND METHOD FOR PRODUCING THE SAME AND METHOD FOR VACCINATION OF VERTEBRATE ANIMALS

Also Published As

Publication number Publication date
ES2243497T3 (en) 2005-12-01
US20020009457A1 (en) 2002-01-24
DE60112073D1 (en) 2005-08-25
EP1280521A2 (en) 2003-02-05
AU2001261433A1 (en) 2001-11-26
HK1049800A1 (en) 2003-05-30
US20040071727A1 (en) 2004-04-15
PT1280521E (en) 2005-10-31
DK1280521T3 (en) 2005-08-08
WO2001087270A2 (en) 2001-11-22
ATE299696T1 (en) 2005-08-15
EP1280521B1 (en) 2005-07-20
US6656470B2 (en) 2003-12-02
WO2001087270A3 (en) 2002-05-16
US7160544B2 (en) 2007-01-09
DE60112073T2 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
WO2001087270B1 (en) Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
RU2000129800A (en) NEW MICROSPHERES BASED ON POLYMETHILIDENMALONATE, METHOD OF THEIR RECOVERY AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
JP6553509B2 (en) Purification of virus-like particles
EP0762875B1 (en) Microparticle delivery system
US6368603B1 (en) Lyme combination compositions and uses
JP3148214B2 (en) New infectious sac disease virus
EP1574210A3 (en) Microemulsions with adsorbed macromolecules and microparticles
WO1997001640A3 (en) Vaccines against hepatitis c
FI79787C (en) Process for the preparation of a live virus vaccine
CA2635430A1 (en) Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
CA2094600C (en) Immunogenic complexes, in particular iscoms
AU3159995A (en) Antigenically-marked non-infectious retrovirus-like particles
WO2001064164A3 (en) Nanocapsule encapsulation system and method
HU229368B1 (en) Novel vaccine composition
DE69720056T2 (en) CHLAMYDIA VACCINALS AND IMMUNOGENIC CHLAMYDIA COMPOSITIONS CONTAINING AN ANTIGUE OF THE OUTER MEMBRANE AND METHOD FOR THE PRODUCTION THEREOF
CN103418254A (en) Method of hydrophilic modification of polyvinylidene fluoride membrane
CA2570050C (en) Heart and skeletal muscle inflammation (hsmi) virus
AU626920B2 (en) The use of zinc hydroxide or iron hydroxide as adjuvant in antigen solutions, and antigen solutions containing such adjuvants
HU211896A9 (en) Chicken anaemia agent vaccine
CA2519806A1 (en) Composition comprising iscom particles and live micro-organisms
CN110236959A (en) A kind of selfreparing self bonding resin cement and preparation method thereof with anti-microbial property
Emini et al. Vero cell‐expressed Epstein‐Barr virus (EBV) gp350/220 protects marmosets from EBV challenge
RU2006114680A (en) HIGH RESISTANT DISPERSIONS OF POLYETHRETHORETHETHYLENE AND METHOD FOR PRODUCING THEM
JPS63202629A (en) Purification of polypropylene glycol modified organosiloxane polymer
EP0187286A1 (en) Oil-adjuvated vaccine and its manufacturing process

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001935330

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001935330

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001935330

Country of ref document: EP